Please assess the completion status of the following clinical trial:

Trial Title: Study to Find the Appropriate Dose of a New Gadolinium-based Contrast Agent (GBCA) for Adults Undergoing Magnetic Resonance Imaging (MRI) for Known or Highly Suspected Brain and/or Spinal Cord Conditions

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Participant must be at least 18 years of age at the time of signing the informed consent.~* Known or highly suspected CNS pathology (contrast-enhancing CNS lesion) referred for contrast-enhanced MRI of the CNS.~* Male and female.~* Estimated glomerular filtration rate (eGFR) value ≥ 60 mL/min/1.73m\^2.~Exclusion Criteria:~* Considered clinically unstable or has a concomitant/intercurrent condition (e.g. COVID-19 infection) that would not allow participation for the full planned study period (i.e. period 1, 2 or both) in the judgement of the investigator.~* Severe cardiovascular disease.~* Patients undergoing liver transplantation.~* Any contraindication to MRI examinations.~* History of severe allergic or anaphylactic/anaphylactoid reaction to any allergen including drugs and contrast agents, foods, chemicals or other substances.~* History of allergic asthma and/ or atopic dermatitis.~* Suspected lesions or suffering from any of the following CNS diseases/lesion types as the main indication for MRI:~  * Lepto-meningeal disease (e.g. leptomeningeal carcinomatosis). Dural lesions (e.g. meningiomas) fulfilling inclusion criteria #2 are not excluded~ * Pituitary adenomas (macro and micro)~ * Tumors of the choroid plexus~ * Tumors of the pineal gland~ * Dermoid/epidermoid tumors~ * Infectious disease (e.g. brain abscess, cisticercosis, etc.)~ * Venous angiomas~ * Subacute/chronic ischemia~ * Encephalitis~ * Multiple sclerosis (acute and chronic)~ * Optic neuritis~ * Chordomas~ * Von Hippel Lindau syndrome~ * Hypertensive leukoencephalopathy.~* Receipt of any contrast agent \< 72 h prior to the study MRIs, or planned receipt of any contrast agent within 72 h after the second study MRI.~* Planned or expected biopsy in the region of interest or any interventional therapeutic procedure from the first study MRI up to 24 h after the second study MRI.~* Planned or expected change in any treatment or procedure between the two study MRIs that may alter image comparability and /or chemotherapy which is changed between the two MRI procedures.~* Contraindications to the administration of gadobutrol, as specified in the local product label.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Gadobutrol + Gadoquatrane (Type: EXPERIMENTAL): Participants will receive one intravenous (IV) injection of gadobutrol 0.1 millimole(s) gadolinium/kilogram body weight (mmol Gd/kg bw) and one IV injection of Gadoquatrane (BAY1747846).

Based on this trial design, predict the completion outcome and termination type (if applicable).